A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines

PHASE2CompletedINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

October 6, 2021

Primary Completion Date

December 2, 2022

Study Completion Date

December 2, 2022

Conditions
Glabellar Lines
Interventions
DRUG

OnabotulinumtoxinA X

Injection

DRUG

Placebo

Injection

Trial Locations (18)

14623

Skin Search of Rochester Inc. /ID# 242540, Rochester

28403

Wilmington Dermatology Center /ID# 242544, Wilmington

43016

Aventiv Research Dublin /ID# 232546, Dublin

70006

Coleman Center For Cosmetic Dermatologic Surgery /ID# 230693, Metairie

85308

Advanced Research Associates - Glendale /ID# 230418, Glendale

99202

Premier Clinical Research /ID# 230682, Spokane

90025-1708

Westside Aesthetics /ID# 230305, Los Angeles

92663-3637

The Eye Research Foundation /ID# 232544, Newport Beach

94115-1809

The Research Center at The Maas Clinic /ID# 230685, San Francisco

20037-1445

Center for Dermatology and Dermatologic Surgery /ID# 230684, Washington D.C.

33431-6465

Steven Fagien MD Aesthetic Eyelid Plastic Surgery /ID# 232542, Boca Raton

33137-3254

Baumann Cosmetic and Research Institute /ID# 232545, Miami

33401-2712

Research Institute of the Southeast, LLC /ID# 230436, West Palm Beach

70130-4353

Etre Cosmetic Dermatology and Laser Center /ID# 230437, New Orleans

63122-3379

SLUCare Cosmetic Dermatology /ID# 230333, St Louis

10016-4974

Laser & Skin Surgery Center of New York /ID# 230683, New York

27517-9901

Aesthetic Solutions /ID# 230716, Chapel Hill

78746-4720

Westlake Dermatology & Cosmetic Surgery - Westlake /ID# 232543, Austin

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Allergan

INDUSTRY